Cargando…

Clinical Outcome of Patients on Ceftazidime–Avibactam and Combination Therapy in Carbapenem-resistant Enterobacteriaceae

INTRODUCTION: Carbapenem-resistant Enterobacteriaceae (CRE) infections have a major effect on mortality as well as healthcare cost. Intensive care units (ICUs) in India, the epicenters for multidrug-resistant organisms, are facing a “postantibiotic era” because of very limited treatment options. A l...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nagvekar, Vasant, Shah, Anand, Unadkat, Vrajeshkumar P, Chavan, Amol, Kohli, Ruhi, Hodgar, Shailendra, Ashpalia, Aashita, Patil, Niranjan, Kamble, Rahul
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Jaypee Brothers Medical Publishers 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8286375/ https://www.ncbi.nlm.nih.gov/pubmed/34316172 http://dx.doi.org/10.5005/jp-journals-10071-23863

Ejemplares similares

Treatment of Carbapenem-Resistant Enterobacteriaceae Infections with Ceftazidime-Avibactam
por: Rahmati, Elham, et al.
Publicado: (2017)

Efficacy of ceftazidime-avibactam in the treatment of infections due to Carbapenem-resistant Enterobacteriaceae
por: Alraddadi, Basem M., et al.
Publicado: (2019)

621. In vitro Ceftazidime: Avibactam Resistance in Carbapenem-Resistant Enterobacteriaceae Isolates
por: Belal, Maymonah, et al.
Publicado: (2019)

Cost-effectiveness analysis of ceftazidime avibactam versus colistin in carbapenem-resistant enterobacteriaceae in Iran
por: Goudarzi, Zahra, et al.
Publicado: (2023)

2262. Ceftazidime–Avibactam vs. Polymyxin B in the Treatment of Infections Due to Carbapenem-Resistant Enterobacteriaceae
por: John, Jamie, et al.
Publicado: (2019)

1885. Cost-Effectiveness of Ceftazidime–Avibactam Compared With Colistin for Treatment of Carbapenem-Resistant Enterobacteriaceae Bacteremia and Pneumonia
por: Sfeir, Maroun, et al.
Publicado: (2018)

1826. Impact of Rapid Diagnostics and Ceftazidime–Avibactam on Mortality after Bacteremia Caused by Carbapenem-Resistant Enterobacteriaceae
por: Satlin, Michael J, et al.
Publicado: (2019)

Clinical Outcomes in Carbapenem-Resistant Enterobacteriaceae Infections Treated With Ceftazidime-Avibactam: A Single-Center Observational Study
por: Rathish, Balram, et al.
Publicado: (2021)

1378. Evaluation of the In vitro Activity of Meropenem-Vaborbactam Against Carbapenem-Resistant Enterobacteriaceae, Including Isolates Resistant to Ceftazidime–Avibactam
por: Wilson, William R, et al.
Publicado: (2018)

Ceftazidime-avibactam with or without Aztreonam vs Polymyxin-based Combination Therapy for Carbapenem-resistant Enterobacteriaceae: A Retrospective Analysis
por: Prayag¹, Parikshit S, et al.
Publicado: (2023)

Ceftazidime-avibactam
por: Matesanz, Mayra, et al.
Publicado: (2021)

Ceftazidime-avibactam
por: Herrero, Francisco Sanz
Publicado: (2022)

Evaluation of the INCREMENT-CPE, Pitt Bacteremia and qPitt Scores in Patients with Carbapenem-Resistant Enterobacteriaceae Infections Treated with Ceftazidime–Avibactam
por: Jorgensen, Sarah C. J., et al.
Publicado: (2020)

2246. Improved Outcomes for Cancer Patients Treated With Ceftazidime–Avibactam vs. Polymyxin-Containing Regimens for Carbapenem-Resistant Enterobacteriaceae Bacteremia
por: Borjan, Jovan, et al.
Publicado: (2019)

Efficacy and safety of ceftazidime–avibactam versus polymyxins in the treatment of carbapenem-resistant Enterobacteriaceae infection: a systematic review and meta-analysis
por: Yang, Ping, et al.
Publicado: (2023)

In vitro Activity of Ceftazidime-Avibactam and Aztreonam-Avibactam Against Carbapenem-resistant Enterobacteriaceae Isolates Collected from Three Secondary Hospitals in Southwest China Between 2018 and 2019
por: Zou, Chunhong, et al.
Publicado: (2020)

Ceftazidime-Avibactam Therapy Versus Ceftazidime-Avibactam-Based Combination Therapy in Patients With Carbapenem-Resistant Gram-Negative Pathogens: A Meta-Analysis
por: Li, Dan, et al.
Publicado: (2021)

662. Recurrence of Infection and Emergence of Drug Resistance After Treatment with Meropenem/Vaborbactam Compared with Ceftazidime/Avibactam in Carbapenem-Resistant Enterobacteriaceae Infections
por: Ackley, Renee, et al.
Publicado: (2019)

In Vitro Activity Comparison of Ceftazidime–Avibactam and Aztreonam–Avibactam Against Bloodstream Infections With Carbapenem-Resistant Organisms in China
por: Yu, Wei, et al.
Publicado: (2021)

A Selective Medium for Screening Ceftazidime/Avibactam Resistance in Carbapenem-Resistant Enterobacterales
por: Zeng, Weiliang, et al.
Publicado: (2022)

In vitro activity of ceftazidime/avibactam against isolates of carbapenem-non-susceptible Enterobacteriaceae collected during the INFORM global surveillance programme (2015–17)
por: Spiliopoulou, Iris, et al.
Publicado: (2020)

Ceftazidime-Avibactam Combination Therapy Compared to Ceftazidime-Avibactam Monotherapy for the Treatment of Severe Infections Due to Carbapenem-Resistant Pathogens: A Systematic Review and Network Meta-Analysis
por: Fiore, Marco, et al.
Publicado: (2020)

Ceftazidime/avibactam for specified infections
Publicado: (2020)

Ceftazidime/Avibactam versus Polymyxin B in the Challenge of Carbapenem-Resistant Pseudomonas aeruginosa Infection
por: Chen, Juan, et al.
Publicado: (2022)

Ceftazidime/Avibactam for the Treatment of Carbapenem-Resistant Pseudomonas aeruginosa Infection in Lung Transplant Recipients
por: Chen, Juan, et al.
Publicado: (2023)

In Vitro Susceptibility to Ceftazidime-Avibactam and Comparator Antimicrobial Agents of Carbapenem-Resistant Enterobacterales Isolates
por: Lim, Tze-Peng, et al.
Publicado: (2023)

Antimicrobial susceptibility testing of Enterobacteriaceae: determination of disk content and Kirby-Bauer breakpoint for ceftazidime/avibactam
por: Yang, Xianggui, et al.
Publicado: (2019)

Evaluation of Ceftazidime/Avibactam Administration in Enterobacteriaceae and Pseudomonas aeruginosa Bloodstream Infections by Monte Carlo Simulation
por: Dai, Yuanyuan, et al.
Publicado: (2021)

1372. In Vitro Activity of Novel Ceftazidime–Avibactam and Aztreonam–Avibactam Combinations Against Carbapenem-Nonsusceptible Enterobacteriaceae Isolates by Phenotype Collected in Latin America From 2014 to 2017 as Part of the INFORM Surveillance Program
por: Kazmierczak, Krystyna, et al.
Publicado: (2018)

1422. Comparative Monte-Carlo Analysis of Aztreonam-Avibactam vs. Ceftazidime–Avibactam Against Carbapenem-Resistant Gram-Negative Pathogens
por: Smith, Aaron, et al.
Publicado: (2018)

In Vitro Activities and Inoculum Effects of Ceftazidime-Avibactam and Aztreonam-Avibactam against Carbapenem-Resistant Enterobacterales Isolates from South Korea
por: Kim, Taeeun, et al.
Publicado: (2020)

Antibacterial Activity and Optimal Treatment of Ceftazidime-Avibactam and Aztreonam-Avibactam Against Bloodstream Infections Caused by Carbapenem-Resistant Klebsiella pneumoniae
por: Yu, Wei, et al.
Publicado: (2021)

Emergence of Ceftazidime/Avibactam and Tigecycline Resistance in Carbapenem-Resistant Klebsiella pneumoniae Due to In-Host Microevolution
por: Han, Xinhong, et al.
Publicado: (2021)

Carbapenem-Resistant Klebsiella pneumoniae Osteomyelitis Treated with Ceftazidime-Avibactam in an Infant: A Case Report
por: Ji, Zejuan, et al.
Publicado: (2021)

Efficacy of Ceftazidime-Avibactam in the Treatment of Carbapenem-Resistant Klebsiella pneumoniae Infection After Kidney Transplantation
por: Zhang, Fei, et al.
Publicado: (2021)

Use of Ceftazidime-Avibactam for Suspected or Confirmed Carbapenem-Resistant Organisms in Children: A Retrospective Study
por: Meng, Haiyang, et al.
Publicado: (2023)

2779. Early Administration of Ceftazidime-Avibactam for Carbapenem-Resistant Enterobacterales Is Associated with Improved Clinical Success
por: Coyne, Ashlan J Kunz, et al.
Publicado: (2023)

Ceftazidime-Avibactam in Combination with In Vitro Non-susceptible Antimicrobials Versus Ceftazidime-Avibactam in Monotherapy in Critically Ill Patients with Carbapenem-Resistant Klebsiella Pneumoniae Infection: A Retrospective Cohort Study
por: Zheng, Guanhao, et al.
Publicado: (2021)

Acetylcysteine increases sensitivity of ceftazidime-avibactam–resistant enterobacterales with different enzymatic resistance to ceftazidime-avibactam in vitro and in vivo
por: Huang, Zeyu, et al.
Publicado: (2023)

Correction to: Ceftazidime-Avibactam in Combination with In Vitro Non-susceptible Antimicrobials Versus Ceftazidime-Avibactam in Monotherapy in Critically Ill Patients with Carbapenem-Resistant Klebsiella Pneumoniae Infection: A Retrospective Cohort Study
por: Zheng, Guanhao, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_4sol6gn7a6dh1bu8u76o7vpr1o